Four molecularly distinct subtypes of uveal melanomas have been identified, two with poorer prognosis and two with better prognosis, according to a study.
Conferences
Researchers develop new melanoma treatment
It’s estimated that one Australian dies of melanoma every five hours. It’s among the most commonly diagnosed cancers in Australia — and the most deadly.
Challenges in melanoma clinical research: A snapshot from the Australasian Melanoma Conference 2016
The last decade has seen a surge in therapeutic options for advanced melanoma patients, thanks to research. However, not every patient responds to treatment and researchers are taking on the challenge to find out why.
ASCO Daily News
Immunotherapies and targeted therapies have been approved for the treatment of metastatic melanoma based on clinical studies. However, in clinical practice, it is not easy to contextualize clinical study data. “Important issues arise when treating real world patients with immunotherapies,” said session chair John B. A. G. Haanen, MD, PhD, of the Netherlands Cancer Institute.